Pacira BioSciences, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
PCRX$36.49+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at December 31, 2025 | 47,891 | (6,774) | $48 | $(176,565) | $1,064,623 | $(199,322) | $4,327 | $693,111 |
| Exercise of stock options | — | — | — | — | 2 | — | — | 2 |
| Vested restricted stock units | 647 | — | — | — | — | — | — | — |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | (210) | — | — | — | (4,355) | — | — | (4,355) |
| Stock-based compensation | — | — | — | — | 13,539 | — | — | 13,539 |
| Purchase of treasury stock, inclusive of excise tax and broker fees | — | (2,245) | — | (50,448) | — | — | — | (50,448) |
| Other comprehensive loss (Note 11) | — | — | — | — | — | — | (872) | (872) |
| Net income | — | — | — | — | — | 2,916 | — | 2,916 |
| Balance at March 31, 2026 | 48,328 | (9,019) | $48 | $(227,013) | $1,073,809 | $(196,406) | $3,455 | $653,893 |
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at December 31, 2024 | 47,078 | (837) | $47 | $(25,121) | $1,009,435 | $(206,356) | $343 | $778,348 |
| Vested restricted stock units | 53 | — | — | — | 1 | — | — | 1 |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | (10) | — | — | — | (181) | — | — | (181) |
| Stock-based compensation | — | — | — | — | 14,553 | — | — | 14,553 |
| Other comprehensive income (Note 11) | — | — | — | — | — | — | 1,008 | 1,008 |
| Net income | — | — | — | — | — | 4,812 | — | 4,812 |
| Balance at March 31, 2025 | 47,121 | (837) | $47 | $(25,121) | $1,023,808 | $(201,544) | $1,351 | $798,541 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.